{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["42(1)"],"submitter":["Zanker J"],"funding":["Australian Medical REsearch Future Fund","Dairy Australia, California Dairy Research Foundation, National Dairy Council, Aarhus University Hospital and Danish Dairy Research Foundation, Fonterra Co-operative Group Ltd, Dutch Dairy Association, Dairy Council of California, Dairy Farmers of Canada, the Centre national interprofessionnel de l'economie laitiere, University of Melbourne, Austin Hospital Medical Research Foundation and Sir Edward Dunlop Medical Research Foundation.","Australian Government Research Training Program (TRP) Scholarship.","Royal Perth Hospital Career Advancement Fellowship (CAF 130/2020),","National Heart Foundation Future Leader Fellowship (ID: 102817).","NHMRC project grant (APP1099173).","National Health and Medical Research Council","Deakin University, Amgen, Department of Health and Human Services (DHHS), and the Norman Beischer Foundation.","NHMRC Postgraduate Scholarship, grant number 2003179.","NHMRC CRE 1102208 and Hospital Research Foundation."],"pubmed_abstract":["<h4>Objectives</h4>To develop guidelines, informed by health-care consumer values and preferences, for sarcopenia prevention, assessment and management for use by clinicians and researchers in Australia and New Zealand.<h4>Methods</h4>A three-phase Consumer Expert Delphi process was undertaken between July 2020 and August 2021. Consumer experts included adults with lived experience of sarcopenia or health-care utilisation. Phase 1 involved a structured meeting of the Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Sarcopenia Diagnosis and Management Task Force and consumer representatives from which the Phase 2 survey was developed. In Phase 2, consumers from Australia and New Zealand were surveyed online with opinions sought on sarcopenia outcome prioritie"],"journal":["Australasian journal on ageing"],"pagination":["251-257"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10947359"],"repository":["biostudies-literature"],"pubmed_title":["The Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) sarcopenia diagnosis and management task force: Findings from the consumer expert Delphi process."],"pmcid":["PMC10947359"],"pubmed_authors":["Dent E","Scott D","Lynch GS","Yu S","Phu S","Grossmann M","Visvanathan R","Hayes A","Hirani V","Pasco JA","Girgis CM","Keogh J","Vlietstra L","Inderjeeth C","Sim M","Daly RM","Brennan-Olsen SL","Iuliano S","Duque G","Walker T","Anderson K","Russell N","Balogun S","Reijnierse EM","Zanker J","Henwood T","Waters DL","Maier AB","Lewis JR"],"additional_accession":[]},"is_claimable":false,"name":"The Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) sarcopenia diagnosis and management task force: Findings from the consumer expert Delphi process.","description":"<h4>Objectives</h4>To develop guidelines, informed by health-care consumer values and preferences, for sarcopenia prevention, assessment and management for use by clinicians and researchers in Australia and New Zealand.<h4>Methods</h4>A three-phase Consumer Expert Delphi process was undertaken between July 2020 and August 2021. Consumer experts included adults with lived experience of sarcopenia or health-care utilisation. Phase 1 involved a structured meeting of the Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Sarcopenia Diagnosis and Management Task Force and consumer representatives from which the Phase 2 survey was developed. In Phase 2, consumers from Australia and New Zealand were surveyed online with opinions sought on sarcopenia outcome prioritie","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-05-18T12:54:46.053Z","creation":"2025-05-18T12:54:46.053Z"},"accession":"S-EPMC10947359","cross_references":{"pubmed":["36480154"],"doi":["10.1111/ajag.13164"]}}